01
Source material
Autologous blood, fat, tissue, cells and non-autologous products are separated.
Regenerative Approaches · Product and Tissue Identity · Istanbul
Autologous blood · Tissue · Product · Cell-related
Regenerative Approaches
PRP, PRF, adipose- or tissue-derived preparations, cell-based approaches, extracellular-vesicle claims and PN/PDRN are not one product class. Source, processing, cellular content, manufacture, authorisation and evidence must remain separate.
The word regenerative does not prove tissue renewal, clinical benefit or durability. Every method below links once to its existing English canonical page.
Physician-Led Orientation
Four levels before method selection
A reasoned sequence begins with the clinical question.
Online review can organise the question. Final suitability follows from in-person examination, the exact product or device and an individual risk–benefit assessment.
02
Processing and content
Cell presence or absence, viability, matrix, soluble factors and manufacturing are made explicit.
03
Licence and evidence
Product, indication, route and regional authorisation are checked together.
04
Clinical boundary
Risks, alternatives, follow-up and a no-treatment option remain visible.
Regenerative Approaches · 01–03
Blood and tissue preparations
Autologous source does not make preparations equivalent.
PRP, PRF and micrografts differ in starting material, processing, cellular content and evidence.
01Existing EN-I4/EN-I5 route
PRP
Autologous plasma fraction; protocol-dependent platelet and cellular composition.
Decision boundaryLinked to one existing canonical; no regenerative outcome is guaranteed.
Open PRP02Existing EN-I4/EN-I5 route
PRF and Autologous Platelet Concentrates
Blood-derived preparations with distinct anticoagulant, clot and processing choices.
Decision boundaryLinked to one existing canonical; no regenerative outcome is guaranteed.
Open PRF and Autologous Platelet Concentrates03Existing EN-I4/EN-I5 route
Polynucleotides, PN and PDRN
Different nucleic-acid-derived products; source, formulation, licence and evidence are product-specific.
Decision boundaryLinked to one existing canonical; no regenerative outcome is guaranteed.
Open Polynucleotides, PN and PDRNRegenerative Approaches · 04–06
Adipose tissue and extracellular-vesicle claims
Tissue structure, cells and manufactured products require separate descriptions.
SVF, microfat/nanofat and exosome-based approaches retain different legal and evidentiary questions.
04Existing EN-I4/EN-I5 route
Exosome-Based Approaches
Product-source, extracellular-vesicle characterisation, manufacturing and authorisation claims require verification.
Decision boundaryLinked to one existing canonical; no regenerative outcome is guaranteed.
Open Exosome-Based Approaches05Existing EN-I4/EN-I5 route
Microfat and Nanofat
Fat- and tissue-derived preparations with different particle, cellular and structural properties.
Decision boundaryLinked to one existing canonical; no regenerative outcome is guaranteed.
Open Microfat and Nanofat06Existing EN-I4/EN-I5 route
Stromal Vascular Fraction (SVF)
Adipose-tissue-derived heterogeneous preparation with processing and regulatory boundaries.
Decision boundaryLinked to one existing canonical; no regenerative outcome is guaranteed.
Open Stromal Vascular Fraction (SVF)Regenerative Approaches · 07–08
Nucleic-acid-derived and cell-based approaches
PN/PDRN and stem-cell approaches are not one biological category.
Source, cell status, manufacture, route, authorisation and evidence remain explicit.
07Existing EN-I4/EN-I5 route
Autologous Microtransplantation
Tissue-derived micrograft preparation; cell and matrix content depend on processing.
Decision boundaryLinked to one existing canonical; no regenerative outcome is guaranteed.
Open Autologous Microtransplantation08Existing EN-I4/EN-I5 route
Stem-Cell-Based Approaches
Cell identity, manipulation, viability, manufacture, indication and regulation must be explicit.
Decision boundaryLinked to one existing canonical; no regenerative outcome is guaranteed.
Open Stem-Cell-Based ApproachesQuality and Safety Framework
Four binding principles
Premium care means clearer selection, boundaries and follow-up.
Advertising language and package logic are replaced by product traceability, anatomy, proportionate alternatives and documented review.
01
Source before slogan
The starting material is named without implying regeneration.
02
Process before equivalence
Preparation and cellular content determine what the product is.
03
Licence before promise
Authorisation is checked by product, route, indication and region.
04
Evidence before repetition
Clinical endpoints and stopping criteria precede another intervention.
Bağdat Caddesi · Istanbul
International patient pathway
Travel, examination and follow-up form one medical process.
The in-person appointment remains the decision point. Product records, early safety, return travel and local medical access are considered before treatment.
- 01
Organise the question
History and records prepare discussion without confirming a biological product.
- 02
Examine and verify
Diagnosis, source, preparation, product status, risks and alternatives are reviewed.
- 03
Keep traceability
Source, processing, batch where relevant, route and observations remain recorded.
- 04
Review without attribution
Safety and agreed endpoints are assessed without assuming every change is regenerative.
The Doctor Aslan Approach
Biological identity before regenerative language
Different preparations keep different medical boundaries.
Doctor Aslan separates source, processing, cellular content, manufacture, authorisation and evidence before considering any clinical role.
Name the source
Blood, fat, tissue, cells and manufactured materials remain distinct.
Audit preparation
Processing and cell presence or absence stay traceable.
Limit the claim
No tissue renewal, collagen response, permanence or personal benefit is guaranteed.
Accept alternatives
Established care, observation or no intervention can take priority.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information; no regeneration, product or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What does the term regenerative approaches mean?+
The term groups very different approaches but is not proof of effectiveness in itself. PRP and PRF use the patient's own blood; microfat, nanofat, SVF and microtransplantation begin with tissue; PN/PDRN and exosome-related offers depend on a product. Material, processing, medical aim, evidence and regulatory status must be named separately for each route.
02Are PRP, PRF, SVF, exosomes and stem-cell approaches comparable?+
No. They differ in biological source, cell or tissue content, collection, processing, product character, invasiveness and legal classification. Data for one preparation, protocol or indication cannot automatically be transferred to another approach. Terms such as cell fraction, exosome and stem cell must not be equated.
03Does autologous material automatically make an application safe and effective?+
No. Autologous material may reduce certain intolerance or transmission risks, but does not make collection and processing risk-free. Bleeding, infection, contamination, tissue damage, unclear composition and an unsuitable indication remain possible. Clinical benefit, personal suitability and the regulatory framework must be assessed independently of origin.
04Which information matters for a regenerative application and travel to Istanbul?+
Diagnosis, medicines, allergies, previous applications and available records belong in advance planning. Products require name, manufacturer, batch, composition and status; autologous blood or tissue also requires collection and processing steps. Review point, warning signs, direct contact and accessible medical help at home are agreed before treatment.
Next Step
Name the source · define the product · examine the evidence